Vaccine Stocks rebounded in premarket trading,with Novavx and Moderna rising over 3%.
Moderna said on Wednesday it had dosed the first participant in a mid-stage study testing its Omicron-specific booster vaccine candidate.
Moreover,a new study has found that a vast majority of people recently infected with Omicron variant say they had already had Covid previously.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments